Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Updated Study Results Show Durable Responses in CLL After Fixed-Duration Ibrutinib-Venetoclax Based on Undetectable MRD

December 11th 2021

The use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia continues to provide deep, durable responses, according to updated results from the MRD cohort of the phase 2 CAPTIVATE trial.

Frontline Venetoclax-Based Combos Improve uMRD Rates Vs Chemoimmunotherapy in Fit Patients With CLL

December 11th 2021

The combination of obinutuzumab and venetoclax (GVe), as well as GVe plus ibrutinib demonstrated superior rates of undetectable minimal residual disease compared with chemoimmunotherapy in fit patients with chronic lymphocytic leukemia, according to findings from the phase 3 GAIA (CLL13) trial.

Frontline Ibrutinib/Venetoclax Induces Higher MRD Clearance and Fewer Relapses in Elderly and Unfit CLL

December 11th 2021

Frontline fixed-duration treatment with ibrutinib plus venetoclax led to deeper and prolonged rates of undetectable minimal residual disease in the bone marrow and peripheral blood, leading to fewer relapses in the first year post-treatment vs chlorambucil plus obinutuzumab in elderly and unfit patients with chronic lymphocytic leukemia.

MRD-Guided Ibrutinib Plus Venetoclax Demonstrates Feasibility in Relapsed/Refractory CLL

December 11th 2021

The minimal residual disease–guided combination of ibrutinib plus venetoclax was found to be a feasible treatment regimen for patients with relapsed/refractory chronic lymphocytic leukemia.

Coombs Previews Anticipated ASH Abstracts in CLL

December 9th 2021

Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.

MRD-Guided Treatment Represents the Future in CLL

December 6th 2021

William G. Wierda, MD, PhD, discussed the results of the phase 2 CAPTIVATE trial and the phase 1/2 TRANSCEND CLL 004 trial, and looked ahead to what the future holds for MRD in patients with CLL.

Pirtobrutinib Provides Promising Results in Richter Transformation

December 6th 2021

Meghan Thompson, MD, discusses the results from the use of pirtobrutinib in the phase 1/2 BRUIN study, as well as upcoming research efforts in the population of patients with Richter transformation.

The Evolving Role of Prognostic Markers for CLL in the Era of Novel Agents

December 3rd 2021

Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

November 30th 2021

The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.

Dr. Stephens on Early Intervention With Targeted Agents in CLL

November 15th 2021

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

November 12th 2021

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Stephens Discusses Optimizing Treatment Selection in CLL

November 9th 2021

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.

Dr. Mato Discusses Advances in the Treatment of Patients With CLL

November 4th 2021

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Testing for Prognostic Markers Is a Necessity for Optimized CLL Care

November 3rd 2021

The identification of prognostic markers at diagnosis in chronic lymphocytic leukemia is critical, says Deborah M. Stephens, DO, who explains that the results of testing for these markers can be used to educate patients on their prognosis, tailor therapy accordingly, and enroll eligible patients on clinical trials.

Dr. Danilov on the Rationale to Target MCL1 and BCLX in CLL

November 1st 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Dr. Roback on Subsequent Treatment Following Ibrutinib Discontinuation in CLL

October 27th 2021

Tadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.

Dr. Modi on the Utility of BTK Inhibitors in CLL

October 26th 2021

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Wierda on Future Research Directions With MRD in CLL

October 25th 2021

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Dr. Robak on the Inclusion Criteria of the RESONATE-2 Trial in CLL

October 25th 2021

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Abutalib on Recent Updates in CLL

October 25th 2021

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.